S U M M A R Y Calcium-activated chloride channels (CLCAs) are a family of multifunctional proteins that are widely distributed in tissues. To investigate the distribution of human CLCA-2 (hCLCA2) in human epithelia at the light and electron microscopic levels, we raised a primary antibody against a synthetic polypeptide sequence from natural hCLCA2. Corneal, skin, vaginal, esophageal, and laryngeal epithelia were immunopositive for hCLCA2 at the cytosolic aspect of the basal cells adjacent to the basement membrane. Epithelia of stomach and small intestine showed no hCLCA2 immunoreactivity. This study reports the cellular distribution of hCLCA2 in human epithelia and suggests its possible involvement in epithelial stratification and cell-substrate adhesion.
C alcium-activated chloride channels (CLCAs) are a new addition to the family of chloride conductance proteins. Thus far, structurally similar members of this transport family have been identified in human, murine, and bovine epithelia (for reviews see Cuppoletti and Malinowska 1999; Fuller et al. 2001; Jentsch et al. 2002) . One intriguing aspect common to this new family is their multifunctional capability. CLCA isoforms have been shown not only to be anion channels but also to mediate cell adhesion (Abdel-Ghany et al. 2001) . In particular the human isoform, hCLCA2, when expressed in the lung, is believed to play a role in modulating the severity of cystic fibrosis . It is also a key molecule in the adhesion of tumor cells to lung endothelia (Abdel-Ghany et al. 2001) and in the tumorigenicity of human breast cancer . To better understand the cellular location of hCLCA2 in human epithelia, an anti-hCLCA2 affinity-purified polyclonal antibody was developed and used to immunolocalize hCLCA2 in cornea, skin, vagina, esophagus, and larynx at the light microscopic level and in corneal epithelium at the electron microscopic level.
The hCLCA2 antibody was prepared from a synthetic peptide corresponding to a non-conserved region on the internal loop between transmembrane domains 3 and 4 (TVEPETGDPVTLRLC) (Takara Bio; Tokyo, Japan). The synthetic peptide was conjugated to keyhole limpet hemocyanin via a C-terminally added cysteine and injected under the skin of a rabbit. After 52 days the IgG fraction of the sera was purified with a protein A column and then affinity-purified with a column filled with a Sepharose-immobilized hCLCA2 synthetic peptide. The reactivity of the anti-hCLCA2 antibody was quantified against immobilized hCLCA2 ( Figure 1A ) and its specificity was shown by successfully labeling HeLa cells transfected with recombinant hCLCA2 ( Figure 1B ). To further prove the specificity of the anti-hCLCA2 antibody, Western blotting of hCLCA2-transfected HeLa and E. coli cells was attempted. However, despite successful transfection of hCLCA2, shown by positive Coomassie Blue staining in E. coli (data not shown), it could not be subsequently detected by the anti-hCLCA2 antibody. Nevertheless, the V5 tag, which was fused to the recombinant hCLCA2 protein during cloning, was detected by antibody staining. This suggests that although the cells were successfully trans-fected with recombinant hCLCA2, the anti-hCLCA2 epitope was denatured during the Western blotting procedure.
Tissue samples for immunohistochemistry (IHC) were obtained from healthy tissue adjacent to tumors excised during surgery on seven individual patients at the Kyoto Prefectural University of Medicine, Japan. Prior informed consent was obtained from each patient after a detailed explanation of the procedures, in accordance with the tenets of the Declaration of Hel-sinki. Immediately after excision, specimens were frozen in Tissue Tek (Miles; Elkhart, IN). Cryosections 7 m thick were collected on silanized glass slides and fixed in Zamboni fixative at 4C for 10 min, followed by multiple washes in 0.01 M PBS. Nonspecific antibody-binding sites were blocked by incubation for 30 min with 0.01 M PBS containing 1% BSA, after which sections were incubated with anti-hCLCA2 antibody ( ϫ 10,000 dilution) for 1 hr at 25C, followed by three 5-min washes in 0.01 M PBS. The sections were then incubated at room temperature (RT) for 1 hr with AlexaFluor 488-conjugated anti-rabbit IgG antibody (Molecular Probes; Eugene, OR). After washing with PBS the sections were mounted in medium containing propidium iodide (Vector; Burlingame, CA) and examined by fluorescent microscopy (Olympus AX70). Negative controls were performed by replacing the primary antibody with nonspecific normal rabbit IgG (DAKO; Kyoto, Japan) at the same concentration. The affinity-purified anti-hCLCA2 antibody detected hCLCA2 in each of the stratified epithelia examined. The expression was primarily limited to the basal membrane of basal cells where the cells were in contact with the basement membranes of the cornea, skin, larynx, vagina and esophagus (Figures 2A-2E ). Nonstratified epithelia of the small intestine and stomach do not express detectable levels of hCLCA2 ) and were included as positive controls. No hCLCA2 immunoreactivity was seen in these tissues ( Figures 2F and 2G ), confirming the validity of our antibody.
Corneal tissue was further examined by immunoelectron microscopy to elucidate more fully the specific location of the hCLCA2 antibody-binding site. For this, the central portion of a human cornea was dissected into small (1 ϫ 2-mm) samples and fixed in 4% paraformaldehyde in 0.1 M PBS for 2 hr at 4C. After dehydration in ethanol (70% and 95% for 15 min and 2 ϫ 100% for 30 min) and infiltration of Unicryl (British Biocell International; Cardiff, UK) overnight, the samples were polymerized in 100% Unicryl at 55C for 48 hr. Ultrathin sections (70-nm) were collected on nickel grids and placed section side down on blocker buffer (0.1 M PBS, 1% goat serum, 0.1% Tween-20, and 1% BSA, adjusted to pH 8.2) for 30 min to reduce nonspecific binding. The grids were then transferred to anti-hCLCA2 antibody ( ϫ 5000 dilution) overnight at 4C, followed by five 5-min washes in blocker buffer and 12-nm gold-labeled anti-rabbit immunoglobulins ( ϫ 25 dilution; Jackson ImmunoResearch, West Grove, PA) for 1 hr at 25C. This was followed by three further washes in blocker buffer, and then sections were allowed to dry overnight. Next day, sections were counterstained with 2% uranyl acetate for 10 min followed by 2% lead citrate for 5 min. Incubations were completed in a moist Figure 1 (A) Reactivity of anti-hCLCA2: enzyme-linked immunosorbent assay. The synthetic peptide was immobilized with 2% glutaraldehyde to a microplate, blocked, and then incubated with a serial dilution of pre-(day 0), rabbit-(day 52), protein A-purified and affinity-purified immune sera for 1 hr. After washing in 0.1 M PBS, the plate was incubated with peroxidase-conjugated anti-rabbit IgG (ICN; Cappel, OH) for 1 hr. Antibody binding was detected with 5 mM 2,2Ј-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) in 0.03% H 2 O 2 . The chromogenic reaction was stopped by addition of 150 mM oxalic acid and optical density was measured at 405 nm in a microplate reader. All incubations were at RT. The reactivity of anti-hCLCA2 after affinity-purification did not notably change. (B) Specificity of anti-hCLCA2: in vitro recombinant protein expression. PCR-amplified fragments of hCLCA2 cDNA sequence was cloned into a mammalian expression vector (pcDNA3.1/V5-His; Invitrogen, Carlsbad, CA) (Holton and Graham 1991) and fused with a V5 tag epitope. Successfully cloned colonies were inoculated to LB medium for 14 hr and plasmids extracted from bacterial pellets with a QIAprep Spin Miniprep Kit (Qiagen; Tokyo, Japan). To select clones without artificial mutation, the plasmids were subjected to a cycle sequence reaction with a BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems; Foster City, CA) followed by gel purification (Princeton Separations; Princeton, NJ). After sequence verification, the purified plasmid was transfected to HeLa cells with transfectamine 2000 (Invitrogen). Transfected cells were fixed with Zamboni's fixative, permeabilized with 70% ethanol, and double immuno-labeled with mouse monoclonal anti-V5 antibody (Invitrogen) and rabbit polyclonal anti-hCLCA2 antibody. Anti-V5 and anti-hCLCA2 were detected with Alexa 594-labeled anti-mouse IgG and Alexa 488-labeled anti-rabbit IgG, respectively, or with preimmune serum as a control. Cells were mounted in medium containing DAPI (Vector; Burlingame, CA).
chamber on 50-l drops. Grids were observed in a Hitachi H-7000 transmission electron microscope at 75 kV. The resulting immunoelectron microscopy of the corneal epithelium disclosed hCLCA2 localization solely to the cytosolic side of the basal aspect of the basal cells, adjacent to the basement membrane. Furthermore, the gold particles appeared primarily in close apposition to the hemidesmosomes, which are positioned regularly along the basal membrane (Figure 3A) .
Previously, mRNA expression of hCLCA2 has been found in lung, mammary gland, and trachea , as well as in cornea (Itoh et al. 2000) .
Here we disclose the presence of hCLCA2 protein in cornea, skin, vagina, esophagus, and larynx. The tissue distribution of hCLCA2 is perhaps an indicator of possible function. Consistent with previous work , we show that hCLCA2 is not present in the non-stratified epithelia of the stomach or small intestine ( Figures 2F and 2G ). However, it is found in all stratified epithelia investigated here and with a similar distribution pattern, thus implying some structural role in epithelial stratification. The integrity of stratified epithelia is maintained by a variety of adhesion mechanisms, including contact via desmosomes at the sites of cell-cell interaction and by hemidesmosomes at the sites of cell-substrate interaction. These sites, in turn, have been linked to the presence of integrin receptors including integrin-␤ 4 , an integral component of the hemidesmosome (Carter et al. 1990; De Luca et al. 1990; Stepp et al. 1990 Stepp et al. ,1993 . In cornea, integrin-␤ 4 is localized specifically to the basal aspect of the basal epithelium (Stepp et al. 1993) , where it has been shown to form an adhesion partner with hCLCA2 during cell-cell contact (Abdel-Ghany et al. 2001) . Our disclosure of hCLCA2 at the basal aspect of the basal cells in the stratified epithelia examined raises the possibility of an involvement with integrin-␤ 4 and a role in basal cell-basement membrane adhesion. This view may go some way to explaining the lack of hCLCA2 in non-stratified epithelia, such as the stomach and small intestine, as shown here, or the colon, spleen, pancreas, and placenta, as shown previously ), if we consider the likelihood that basal cell-basement membrane adhesion in such tissues will encounter lower shearing forces than those encountered by stratified epithelia.
In conclusion, this study provides the first comprehensive results showing hCLCA2 localization at the cellular level in human epithelial tissues. The data indicate a specific localization of hCLCA2 towards the basal side of the basal cells of stratified epithelium, and, in cornea, apparent co-localization with hemidesmosomes. These observations are in marked contrast to those from the non-stratified epithelia investigated here, which indicate an absence of hCLCA2. The physiological role of hCLCA2 requires further elucidation. Nevertheless, the current results point to the involvement of hCLCA2 in epithelial stratification and possibly in cell-substrate adhesion.
